A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2017
At a glance
- Drugs APX 3330 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Apexian Pharmaceuticals
- 12 Dec 2017 Status changed from planning to not yet recruiting.
- 05 Jun 2017 According to an Apexian Pharmaceuticals media release, the company expects to initiate this trial in 2017.
- 01 Mar 2017 According to an ApeX Therapeutics media release, the US FDA has granted authorization to initiate this trial.